CoChat

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial.Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at 371 sites in 24 countries. Men and women (aged ≥50 years) with established or newly detected type 2 diabetes whose HbA 1c was 9·5% or less (with no lower limit) on stable doses of up to two oral glucose-lowering drugs with or without basal insulin therapy were eligible if their body-mass index was at least 23 kg/m 2. Participants were randomly assigned (1:1) to weekly subcutaneous injections of either masked dulaglutide 1·5 mg or the same volume of masked placebo (containing the same excipients but without dulaglutide). Randomisation was done by a computer-generated random code with an interactive web response system with stratification by site. Participants, investigators, the trial leadership, and all other personnel were masked to treatment allocation until the trial was completed and the database was locked. During the treatment period, participants in both groups were instructed to inject study drug on the same day at around the same time, each week. Strokes were categorised as fatal or non-fatal, and as either ischaemic, haemorrhagic, or undetermined. Stroke severity was assessed using the modified Rankin scale. Participants were seen at 2 weeks, 3 months, 6 months, and then every 3 months for drug dispensing and every 6 months for detailed assessments, until 1200 confirmed primary outcomes accrued. The primary endpoint was the first occurrence of any component of the composite outcome, which comprised non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular or unknown causes. All analyses were done according to an intention-to-treat strategy that included all randomly assigned participants, irrespective of adherence. The trial is registered with ClinicalTrials.gov, number NCT01394952.Findings Between Aug 18, 2011, and Aug 14, 2013, we screened 12 133 patients, of whom 9901 with type 2 diabetes and additional cardiovascular risk factors were randomly assigned to either dulaglutide (n=4949) or an equal volume of placebo (n=4952). During a median follow-up of 5·4 years, cerebrovascular and other cardiovascular outcomes were ascertained and adjudicated. 158 (3·2%) of 4949 participants assigned to dulaglutide and 205 (4·1%) of 4952 participants assigned to placebo had a stroke during follow-up (hazard ratio [HR] 0·76, 95% CI 0·62-0·94; p=0·010). Dulaglutide reduced ischaemic stroke (0·75, 0·59-0·94, p=0·012) but had no effect on haemorrhagic stroke (1·05, 0·55-1·99; p=0·89). Dulaglutide also reduced the composite of non-fatal stroke or all-cause death (0·88, 0·79-0·98; p=0·017) and disabling stroke (0·74, 0·56-0·99; p=0·042). The degree of disability after stroke did not differ by treatment group.Interpretation Long-term dulaglutide use might reduce clinically relevant ischaemic stroke in people with type 2 diabetes but does not affect stroke severity.Funding Eli Lilly and Company.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30423-1

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 23 references

Cited by

See all 137

Metadata

Authors
Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., Dyal, L., Hall, S., Avezum, A., Basile, J., Conget, I., Cushman, W. C., Hancu, N., Hanefeld, M., Jansky, P., Keltai, M., Lanas, F., Leiter, L. A., Lopez-Jaramillo, P., Muñoz, E. G. C., Pogosova, N., Raubenheimer, P. J., Shaw, J. E., Sheu, W. H.-H., & Temelkova-Kurktschiev, T.
Affiliations
  • Population Health Research Institute (CA)
  • University of Edinburgh (GB)
  • Eli Lilly (United States) (US)
  • University of Washington (US)
  • Oregon Health & Science University (US)
  • Karolinska Institutet (SE)
  • Medical University of South Carolina (US)
  • Hospital Clínic de Barcelona (ES)
  • Memphis VA Medical Center (US)
  • Universidad de La Frontera (CL)
  • St. Michael's Hospital (CA)
  • Universidad de Guadalajara (MX)
  • University of Cape Town (ZA)
  • Baker Heart and Diabetes Institute (AU)
  • Taichung Veterans General Hospital (TW)
  • Bulgarian National Bank (BG)
Corresponding author
Gerstein, Hertzel C
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2020-02
Volume
8
Issue
2
Pages
106-114
ISSN
2213-8587 (ISSN-L)
OpenAlex
W3000040775
Cited by
137
References
23
Citations by year
2026: 9 · 2025: 15 · 2024: 29 · 2023: 24 · 2022: 18 · 2021: 27 · 2020: 15
FWCI
15.76
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • Repositorio Universidad de Santander (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Omeka S (Universidad de La Frontera) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
dulaglutide, stroke, GLP-1 receptor agonists, type 2 diabetes, REWIND trial, ischemic stroke, hemorrhagic stroke, cardiovascular outcomes, modified Rankin Scale, stroke severity, cardiovascular risk factors, myocardial infarction, cardiovascular mortality, type 1 diabetes, type 3 diabetes
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Prospective Studies, Recombinant Fusion Proteins, Treatment Outcome, Stroke, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30423-1
The paper
Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., Dyal, L., Hall, S., Avezum, A., Basile, J., Conget, I., Cushman, W. C., Hancu, N., Hanefeld, M., Jansky, P., . . . Temelkova-Kurktschiev, T. (2020). The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30423-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.